# Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

> **NCT05321498** · PHASE2 · WITHDRAWN · sponsor: **Inmune Bio, Inc.**

## Conditions studied

- Mild Cognitive Impairment (MCI)
- Alzheimer Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Tauopathies
- Neurodegenerative Diseases
- Mental Disorders

## Interventions

- **DRUG:** XPro1595
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05321498
- **Lead sponsor:** Inmune Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-10-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** MCI patients will now be enrolled in the XPro1595-AD-02 study.
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05321498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05321498, "Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05321498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*